Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

Autor: Remon Masip, J., Bironzo, P., Girard, N., Bigay-Game, L., Juan Vidal, O.J., de Castro Carpeño, J., Reguart Aransay, N., Greillier, L., Cousin, S., Dansin, E., Majem, M., Bernabe Caro, R., Mosquera Martinez, J., Diaz, M., Meya, A., Alcalá-López, D., Sanz, A.G., Righi, L., Novello, S., Besse, B.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S1270-S1270

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis

Autor: Dafni, U., Soo, R. A., Peters, S., Tsourti, Z., Vervita, K., Han, J-Y., De Castro, J., Coate, L., Frueh, M., Hashemi, S. M. S., Nadal, E., Carcereny, E., Sala Gonzalez, M. Angeles, Bernabe Caro, R., Provencio Pulla, M., Cuffe, S., Ruepp, B., Roschitzki-Voser, H., Rosell, R., Stahel, R. A.

Publikováno v: Annals of Oncology, 33, S46-S47. Oxford University Press
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Frueh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala Gonzalez, M A, Bernabe Caro, R, Provencio Pulla, M, Cuffe, S, Ruepp, B, Roschitzki-Voser, H, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis ', Annals of Oncology, vol. 33, pp. S46-S47 . https://doi.org/10.1016/j.annonc.2022.02.041

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::64418512fae0d484e5ce8ebd614883eb
https://research.vumc.nl/en/publications/d5c9a352-1e46-4991-8903-14041df7240f

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Autor: Majem, M, Cobo, M, Isla, D, Marquez-Medina, D, Rodriguez-Abreu, D, Casal-Rubio, J, Moran-Bueno, T, Bernabe-Caro, R, Perez-Parente, D, Ruiz-Gracia, P, Arroyo, MM, Paz-Ares, L

Publikováno v: Journal of Clinical Medicine
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0d08ad6c95fe9fda85153cb3c63e834c
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4850